incretin hormone is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2026-05-31. Where a claim depends on a specific study, the study is described rather than over-claimed.
Lyophilised material appears as a white to off-white cake or powder that is hygroscopic, and containers are usually equilibrated to room temperature before opening to limit condensation. Dissolution is performed in water, phosphate-buffered saline, or a mildly alkaline buffer, since solubility rises above neutral pH. Gentle inversion or low-speed mixing is preferred, because vigorous vortexing can promote surface denaturation and aggregation. Complete dissolution may require several minutes, and brief sonication is sometimes applied. Passing the solution through a 0.22 micrometre membrane removes particulates but does not by itself sterilise the liquid.
Storage at minus 20 degrees Celsius or lower in a desiccated container preserves the peptide for extended periods, while working solutions are commonly held at two to eight degrees Celsius for short intervals. Light exposure and repeated freeze-thaw cycles accelerate degradation, so dividing material into single-use aliquots is generally recommended. Adsorption to glass and plastic surfaces can lower the measured concentration of dilute solutions, particularly below one milligram per millilitre. The degradation routes most often reported for GLP-1 analogues are deamidation, methionine oxidation, and backbone hydrolysis. Relative rates under specific conditions are frequently described only for individual formulations.
Pharmacological activity arises from agonism at the glucagon-like peptide-1 receptor, a G protein-coupled receptor expressed in the pancreas, the gastrointestinal tract, and the brainstem. Receptor activation raises intracellular cyclic adenosine monophosphate and enhances insulin release in a glucose-dependent manner, an effect that diminishes when blood glucose concentration is low. Other effects include slowed gastric emptying and hypothalamic satiety signalling. These pathways are described well. Receptor desensitisation rates across tissues, relative to the endogenous hormone, are still under investigation, and reported findings differ between laboratories.
The company that developed the compound filed it as a long-acting analogue, and it gained first approval in 2017 for type 2 diabetes. Later authorisations from several regulators extended the indication to chronic weight management, and the World Health Organization added the glucagon-like peptide-1 receptor agonist drug class to its model list of essential medicines in 2023. Production uses solid-phase peptide synthesis followed by side-chain conjugation and chromatographic purification. Supply constraints and cost differences across regions are well documented. Literature on long-term outcomes continues to grow, with many trials reporting surrogate endpoints rather than hard clinical endpoints.
| Property | Value | Notes |
|---|---|---|
| Purity assessment | RP-HPLC, 214 nm | Wavelength affects relative peak areas |
| Identity confirmation | LC-MS/MS | Precursor and fragment ion masses compared |
| Common degradation | Deamidation, oxidation | Amide and methionine residues are main sites |
| Working solution storage | 2-8 °C, short term | Longer holding favours frozen aliquots |
| Adsorption risk | Higher below 1 mg/mL | Glass and plastic surfaces both affected |
Receptor activation raises intracellular cyclic AMP through Gs coupling, which promotes glucose-dependent insulin release and suppresses glucagon secretion when blood glucose is elevated. Effects outside the pancreas include slower gastric emptying and altered appetite signalling in the hypothalamus and hindbrain. The relative contribution of each tissue to overall metabolic outcomes remains an area of active investigation. Central mechanisms in particular are inferred mainly from animal models and indirect human measures rather than direct observation.
Serum protein binding dominates the pharmacokinetic profile. The attached chain associates strongly with albumin, shielding the peptide from enzymatic attack and slowing filtration by the kidney. This interaction extends the circulation half-life to roughly one week in humans, which supports weekly administration intervals. An oral version pairs the peptide with an absorption enhancer that transiently alters gastric epithelium, permitting limited uptake; bioavailability by that route is substantially lower than by injection.
Semaglutide belongs to the glucagon-like peptide-1 receptor agonist class, a group of synthetic peptides that imitate an incretin hormone released by intestinal L cells after food intake. Native GLP-1 circulates for only a few minutes because dipeptidyl peptidase-4 cleaves it rapidly. The hormone acts on pancreatic islets, the gastrointestinal tract, and several brain regions. Because the natural peptide is short-lived, development work concentrated on analogues that keep receptor activity while resisting enzymatic breakdown and renal clearance.
Lyophilized semaglutide is typically stored at temperatures between minus 20 and minus 80 degrees Celsius for long-term preservation. Short-term storage at 2 to 8 degrees Celsius is common for working aliquots. Repeated freeze-thaw cycles can degrade the peptide and are usually avoided. The molecule is hygroscopic in its solid form, so containers should remain sealed with desiccant. Solutions are less stable than powders and are generally prepared fresh. Light exposure is limited because aromatic residues can undergo photo-oxidation.
Semaglutide dissolves readily in water and in aqueous buffers near neutral pH. Solubility decreases near the isoelectric point, where net charge is minimal. Common laboratory solvents include phosphate-buffered saline and dilute ammonium bicarbonate. Strongly acidic or basic conditions may accelerate hydrolysis. Working concentrations are usually prepared by diluting a concentrated stock. Vial surfaces can adsorb small amounts of peptide at low concentrations, so carrier proteins or low-binding tubes are sometimes used.
Reverse-phase high-performance liquid chromatography is the standard method for purity assessment, separating the peptide from truncated or oxidized variants. Mass spectrometry confirms molecular mass and detects modifications, while ultraviolet absorbance near 280 nanometers supports concentration measurement through tryptophan and tyrosine residues. Circular dichroism can indicate secondary structure, though the peptide is largely helical in solution, and ion-exchange chromatography resolves charge variants. Purity values above 95 percent are typical for research-grade material. Stability studies track degradation over time under defined conditions.
=== Acquisitions === In 1989, after a four-month legal dispute to avoid a takeover, Church's Chicken became the second-largest chicken restaurant chain when it was acquired by Popeyes for $330 million. The acquisition court documents stated that Church's Chicken would close 250 of its restaurants, "keep 92 with the Church's name, rename 303 others as Popeyes and sell 440 others for about $160 million over the next four years". Merrill Lynch and a group of banks led by Canadian Imperial financed the acquisition. In 1992, Popeyes' parent company, Al Copeland Enterprises, Inc., was forced to file chapter 11 bankruptcy for the more than $400 million debt it owed its creditors for the Church's Chicken buyout. In 1993, Al Copeland Enterprises, Inc. was renamed AFC Enterprises, Inc., or America's Favorite Chicken, and became the parent company of Church's Chicken and Popeyes. In 2004, Arcapita bought Church's Chicken from AFC Enterprises, Inc., and former Domino's Pizza and Little Caesars executive Harsha Agadi became president and CEO of Church's Chicken. In 2005, because Arcapita invests in companies that respect Shari'ah principles, it removed pork products from the Church's Chicken menu. In 2007, AFC Enterprises, Inc. filed a lawsuit against Church's Chicken and former franchise group CVI Company, for allegedly colluding to breach Popeyes' franchise, development and guaranty agreements with CVI, when "Church's [Chicken] bought all 10 of CVI's Popeyes' restaurants and converted most of them to the Church's Chicken brand".
where the solubility product for [Ca2+][CO2−3] is given as anywhere from Ksp = 3.7×10−9 to Ksp = 8.7×10−9 at 25 °C, depending upon the data source. What the equation means is that the product of molar concentration of calcium ions (moles of dissolved Ca2+ per liter of solution) with the molar concentration of dissolved CO2−3 cannot exceed the value of Ksp. This seemingly simple solubility equation, however, must be taken along with the more complicated equilibrium of carbon dioxide with water (see carbonic acid). Some of the CO2−3 combines with H+ in the solution according to
=== Chronic cholecystitis === Chronic cholecystitis occurs after repeated episodes of acute cholecystitis and is almost always due to gallstones. Chronic cholecystitis may be asymptomatic, may present as a more severe case of acute cholecystitis, or may lead to a number of complications such as gangrene, perforation, or fistula formation. Xanthogranulomatous cholecystitis (XGC) is a rare form of chronic cholecystitis which mimics gallbladder cancer although it is not cancerous. It was first reported in the medical literature in 1976 by McCoy and colleagues.
== Notable achievements and awards == In 1996, Kessler became a member of the Bavarian Academy of Sciences and Humanities, one of the eight state academies in Germany. In 2002, he was elected to membership of the Academy of Sciences Leopoldina, the national academy of Germany.
Sources: en.wikipedia.org
===== Type 2M ===== VWD Type 2M results from a loss-of-function mutation in von Willebrand factor (VWF). This mutation leads to reduced binding of VWF with GP1b (similar to VWD Type 2A) or with collagen. Like other Type 2 VWD subtypes, there is a decreased ratio of VWF Activity to antigen. Differentiating VWD Type 2M from Type 2A involves analyzing VWF multimers through electrophoresis. In VWD Type 2M, all multimers are identified but uniformly decreased in quantity, resembling the pattern seen in VWD Type 1. Conversely, in VWD Type 2A, high molecular weight multimers are either absent or present in very low quantities. VWD Type 2M can be further differentiated from VWD Type 1 based on the VWF Activity to antigen ratio. In Type 1, the ratio is >0.7. In Type 2M, the ratio is <0.7. In Type 2M, factor VIII activity can be normal or low while the ristocetin-induced platelet aggregation (RIPA) is typically low. It is uncommon and manifests with moderate to severe bleeding. The disease may follow either an autosomal dominant or recessive pattern of inheritance.
The pH of the collagen is then reduced so the enzymes may act on it in a process known as deliming. Depending on the end use of the leather, hides may be treated with enzymes to soften them, a process called bating. In modern tanning, these enzymes are purified agents, and the process no longer requires bacterial fermentation (as from dung-water soaking) to produce them.
Laidlaw stated that reasons behind the cancellation included the fact that headcrabs and zombies "were pretty much played out at the time", and that the fact that it had to take place chronologically prior to Half-Life 2: Episode Two was too creatively constraining. Footage of the project was shown in a 2020 documentary by media company Noclip titled The Untold History of Arkane.
Sources: en.wikipedia.org
Filtering removes particulate matter that can block columns or scatter light. A 0.22 micrometre membrane is typical, and the filter material should be checked for peptide adsorption.
Peptides can bind to glass and plastic, so a fraction of the material leaves the solution. The effect is proportionally larger in dilute samples and can bias quantitative results.
Reverse-phase high-performance liquid chromatography is the most widely reported approach. Purity figures should always be quoted together with the wavelength, gradient, and integration parameters used.
It is a glucagon-like peptide-1 receptor agonist, often grouped with the incretin mimetics. Its backbone is modified from the human hormone to resist enzymatic degradation and to bind albumin. These two features distinguish it from the native peptide.